Compositions against cancer antigen LIV-1 and uses thereof
View Patent ↗Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
1. A monoclonal antibody that specifically binds to a protein having the amino acid sequence of SEQ ID NO:2, wherein the antibody is selected from the group consisting of BR2-14a, which is produced by the hybridoma having ATCC accession number PTA-5705, BR2-19a, which is produced by the hybridoma having ATCC accession number PTA-5706, BR2-22a, which is produced by the hybridoma having ATCC accession number PTA-11478, and BR2-23a, which is produced by the hybridoma having ATCC accession number PTA-5707, or a chimeric or humanized form thereof.
2. The antibody of claim 1 , wherein the antibody is a humanized form of the antibody.
3. The antibody of claim 1 , wherein the antibody is a humanized form of BR2-14a.
4. The antibody of claim 1 , wherein the antibody is a humanized form of BR2-19a.
5. The antibody of claim 1 , wherein the antibody is a humanized form of BR2-23a.
6. The antibody of claim 1 , wherein the antibody is an antigen-binding fragment.
7. The antibody of claim 1 , wherein the antibody is conjugated to an effector component.
8. The antibody of claim 7 , wherein the effector component is selected from the group consisting of a fluorescent label, a radioisotope or a cytotoxic chemical.
9. The antibody of claim 8 , wherein the cytotoxic chemical is auristatin-E or monomethyl auristatin E.
10. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the antibody of claim 1 .
11. The pharmaceutical composition of claim 10 , wherein the antibody is an antigen-binding fragment.
12. The pharmaceutical composition of claim 10 , wherein the antibody is conjugated to an effector component comprising a radioisotope or a cytotoxic chemical.
13. The pharmaceutical composition of claim 12 , wherein the cytotoxic chemical is auristatin-E or monomethyl auristatin E.
14. A hybridoma having ATCC Accession No. PTA-5705.
15. A hybridoma having ATCC Accession No. PTA-5706.
16. A hybridoma having ATCC Accession No. PTA-5707.
17. A hybridoma having ATCC Accession No. PTA-11478.
18. The antibody of claim 1 , wherein the antibody is the humanized form of BR2-22a.